Evicenter
Qulipta (atogepant) in Preventive treatment of migraine
Manufacturer
AbbVie Inc.
Prescribing information
Qulipta (opens in a new tab)
Questions
71
Last updated

All questions

Access and coverage: Qulipta (atogepant) in preventive treatment of migraine

12 questions · 3 sources

Cost and coverage

Is there a Qulipta savings card (copay card)?

How much do patients pay for Qulipta with the savings card?

Note: The prior authorization guide on the same site (dated July 2025) states 94%, based on savings card redemption data from January to December 2024. The figure quoted here is from the access and coverage page and uses 2025 data.

How do patients activate the Qulipta savings card?

Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links. The second passage begins the footnote marked † in the first, and the last passage is the footnote marked * in the third.

Can Medicare patients use the Qulipta savings card?

Is Qulipta covered by commercial insurance?

Note: The QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links states that 98% of nationally commercially insured lives are covered, and its pages 1 and 2 state the share covered with zero steps as 64% (page 1) and 62% (page 2), all with MMIT data as of December 2024. The figures quoted from the access and coverage page give 98% and 64% for 2026 (data as of January 2024 and August 2026); the page was captured on November 14, 2026.

How many Medicare Part D lives can get Qulipta with no step therapy?

Note: The figure carries the marks 3, †, and §. The page prints two footnotes marked §, both quoted here: one below the local coverage lookup (data as of May 2026) and one in the footnote list that follows the Medicare figure (data as of January 2026). The page was captured on November 14, 2026.

Prior authorization

What are the Qulipta prior authorization requirements?

Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links.

How should a Qulipta PA request for continuing therapy be filed?

Note: The passage is from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links.

Does Qulipta require step therapy?

Note: The QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links states that 98% of nationally commercially insured lives are covered, and its pages 1 and 2 state the share covered with zero steps as 64% (page 1) and 62% (page 2), all with MMIT data as of December 2024. The figures quoted from the access and coverage page give 98% and 64% for 2026 (data as of January 2024 and August 2026); the page was captured on November 14, 2026. The step therapy examples are from page 5 of that guide.

What are common PA denial reasons in the Qulipta prior authorization guide?

Note: The passages are from the QULIPTA prior authorization guide (US-QLP-250340, July 2025) that the downloadable resources page links. The guide cites AbbVie data on file (its reference 1) for the denial reasons and does not state that they are specific to QULIPTA.

Access and support

What prior authorization and appeal resources does Qulipta offer?

Are Qulipta samples available for prescribers?

Note: The downloadable resources page offered sample ordering when it was captured on November 14, 2026.